TriSalus Life Sciences (TLSI) Stock Fair Value Moves Lower After Q3 Miss And Guidance Reset
Canaccord Genuity Maintains Buy on TriSalus Life Sciences, Lowers Price Target to $4
HC Wainwright & Co. Maintains Buy on TriSalus Life Sciences, Lowers Price Target to $10
TriSalus Life Sciences, Inc. Q3 2026 Earnings Call Summary
TriSalus: 3 Key Takeaways for Long-Term Investors
TriSalus (TLSI) Q3 2026 Earnings Call Transcript
TriSalus Life Sciences Q3 Earnings Call Highlights
TriSalus Life Sciences Reports 11.3% Q3 Revenue Growth to $12.9 Million, Revises 2026 Guidance
Trisalus Life Sciences (NASDAQ:TLSI) Shares Fall as Q3 Revenue and 2026 Guidance Miss Estimates
TriSalus Life Sciences, Inc. (TLSI) Q3 2026 Earnings Call Transcript
TriSalus Life Sciences Reports Third Quarter 2026 Results
TriSalus Life Sciences Q3 2026 Earnings Call Transcript
TriSalus Life Sciences, Inc. 2026 Q3 - Results - Earnings Call Presentation
TriSalus Life Sciences Lowers FY2026 Sales Guidance from $54.000M-$57.000M to $46.000M-$48.000M vs $53.119M Est
TriSalus Life Sciences Q3 EPS $(0.15) Misses $(0.13) Estimate, Sales $12.900M Miss $14.024M Estimate
TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum
TriSalus Life Sciences to Host Third Quarter 2026 Financial Results Conference Call
Full Transcript: TriSalus Life Sciences Q2 2026 Earnings Call
TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support
TriSalus Life Sciences Shares Rise 15.6% After FDA Clearance for TriNav Advance
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.